Osteopore's A$18.7m partnership with NDCS and A*STAR hits key milestones

Osteopore Limited (ASX: $OSX) has achieved significant progress in its A$18.7m clinical-industrial partnership with the National Dental Centre Singapore (NDCS) and the Agency for Science, Technology and Research (A*STAR). The project has successfully developed a 3D-printing technology capable of combining patented biological additives and polymer compounds for dental implants, with the potential to accelerate bone healing. The next phase involves in vivo studies in biological models to assess the efficacy of bone regeneration.

CEO Dr Yujing Lim expresses excitement for project outcomes

We are excited by the outcomes of this project so far and appreciate the support of our partners at A*STAR and NDCS. We are delighted with the dedication of our partners towards ensuring that project milestones are met.

Project outlook and market potential

Osteopore's successful development of a 3D-printing technology for next-generation dental implants marks a significant achievement in the A$18.7m partnership with NDCS and A*STAR. The project's progression to in vivo studies signifies a promising outlook for the potential of bone regeneration. With the global dental bone graft and membrane substitutes market projected to reach USD$27.55 billion by 2030, Osteopore's next-generation dental implants position the company to tap into this lucrative market and align with its long-term vision of becoming a global leader in regenerative medicine.